Protalix BioTherapeutics is a commercial-stage biopharmaceutical company focused on discovery, development, production, and commercialization of therapeutics for rare diseases. It uses its proprietary ProCellEx plant cell-based protein expression system. Its approved products include Elelyso (taliglucerase alfa) for Gaucher disease and Elfabrio (pegunigalsidase alfa) for Fabry disease. Pipeline candidates include PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases.
Q2 FY2026 — expected 2026-08-21
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-18 | 2025-12-31 | 0001104659-26-029858 | EDGAR | 68K words |
| 2025-03-17 | 2024-12-31 | 0001558370-25-003039 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0001558370-24-003161 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001558370-23-002102 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0001558370-22-004823 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001558370-21-003681 | EDGAR | — |
| 2020-03-12 | 2019-12-31 | 0001104659-20-032540 | EDGAR | — |
| 2019-03-18 | 2018-12-31 | 0001144204-19-014464 | EDGAR | — |
| 2018-03-06 | 2017-12-31 | 0001144204-18-013053 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001144204-17-015083 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001104659-25-110824 | EDGAR | 22K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011471 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001558370-25-007063 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0001558370-24-015612 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0001558370-24-012134 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001558370-24-007695 | EDGAR | — |
| 2023-11-06 | 2023-09-30 | 0001558370-23-017664 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0001558370-23-013483 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0001558370-23-008132 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001558370-22-017554 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0001558370-22-013560 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001558370-22-008847 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-18 | 0001104659-26-029846 | EDGAR | 4K words |
| 2026-03-09 | 0001104659-26-024975 | EDGAR | — |
| 2026-02-11 | 0001104659-26-013498 | EDGAR | — |
| 2026-01-30 | 0001104659-26-008410 | EDGAR | — |
| 2026-01-05 | 0001104659-26-000393 | EDGAR | — |
| 2025-11-13 | 0001104659-25-110821 | EDGAR | — |
| 2025-11-03 | 0001104659-25-105594 | EDGAR | — |
| 2025-10-17 | 0001104659-25-100264 | EDGAR | — |
| 2025-08-22 | 0001104659-25-081924 | EDGAR | — |
| 2025-08-14 | 0001558370-25-011468 | EDGAR | — |
490 total filings indexed. 458 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001006281 |
| Ticker | PLX |
| Exchange | NYSE |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.protalix.com |
| Listed | 1996-01-02 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report